Zynex Inc. Revenue and EPS Estimates Cut Sharply by Analysts

Zynex, Inc. (NASDAQ:ZYXI) analysts have revised down their statutory forecasts for this year, with both revenue and earnings per share estimates cut sharply. The consensus now predicts revenues of $117m in 2025, a 32% decline compared to last year, and per-share losses of $0.78. The consensus price target fell 40% to $6.00, with analysts concerned about the company's weaker revenue and earnings outlook.

Zynex, Inc. (NASDAQ:ZYXI), a biotechnology company specializing in drug discovery and development, has seen its analysts revise their 2025 forecasts downward. The consensus now predicts revenues of $117 million for the year, a 32% decline compared to last year. Additionally, analysts expect the company to report per-share losses of $0.78. The consensus price target has fallen 40% to $6.00, reflecting concerns about Zynex's weaker revenue and earnings outlook [1].

The revised estimates come on the heels of Zynex's Q1 2025 earnings report, where the company reported an earnings per share (EPS) of -$0.33, missing the consensus estimate of -$0.24 by $0.09. Quarterly revenue was $26.58 million, below analyst estimates of $30.83 million [1].

Zynex's earnings are expected to grow from $0.20 per share to $0.47 per share in the next year, which is a 135.00% increase. However, the recent downward revision in forecasts suggests that analysts are now more pessimistic about the company's financial performance in 2025 [1].

The company has a trailing price-to-earnings ratio of 15.40 and a forward price-to-earnings ratio of 11.55. With the recent downward revision in earnings and revenue estimates, investors should closely monitor Zynex's future earnings reports and guidance to assess the potential impact on the company's stock price [1].

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/ZYXI/earnings/